Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
07/08/2016
Trade Name:
Dexilant
Generic Name or Proper Name (*):
dexlansoprazole
Indications Studied:
Healing of erosive esophagitis (EE), maintenance of healed EE and relief of heartburn, and treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD) in 12 to 17 years
Label Changes Summary:
*Safety and effectiveness of Dexilant capsules have been established in pediatric patients 12 to 17 years for the healing of all grades of EE. *The safety and effectiveness of Dexilant capsules and Dexilant SoluTab have been established in pediatric patients 12 to 17 years for the maintenance of healed EE and relief of heartburn, and treatment of heartburn associated with symptomatic non-erosive GERD. *Use in this age group is supported by evidence from adequate and well-controlled studies of Dexilant capsules in adults with additional safety, efficacy and pharmacokinetic data in pediatric patients 12 to 17 years. *Safety and effectiveness have not been established in pediatric patients less than 12 years. *Use of Dexilant is not recommended for symptomatic non-erosive GERD in pediatric patients less than 1 year because studies in this class of drugs have not demonstrated efficacy. *Adverse reactions similar to those observed in adults. *Information on dosing, adverse reactions, clinical trials. *Postmarketing study.
Product Labeling:
Labeling
PREA(P):
P
Sponsor:
Takeda
NNPS:
FALSE
Therapeutic Category:
Antiulcerative
-
-